Englewood, Colo.-based Ampio Pharmaceuticals Inc. plans to sell its common shares and accompanying warrants to buy common shares in an underwritten public offering.

The clinical trial stage biopharmaceutical company will sell all of the securities in the proposed offering.

Net proceeds from the offering will be used for working capital and general corporate purposes, including continued preclinical development of Ampion and funding an Ampion clinical trial, if required.

Canaccord Genuity is acting as sole book-running manager for the proposed offering.